(VIANEWS) – Banco Santander (BSAC), Century Communities (CCS), Terreno Realty Corporation (TRNO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Banco Santander (BSAC)
34.7% sales growth and 13.86% return on equity
Banco Santander-Chile, together with its subsidiaries, provides commercial and retail banking products and services in Chile. It operates through Retail Banking, Middle-Market, and Corporate Investment Banking segments. The company offers debit and credit cards, checking accounts, and savings products; consumer, automobile, commercial, mortgage, and government-guaranteed loans; and Chilean peso and foreign currency denominated loans to finance various commercial transactions, trade, foreign currency forward contracts, and credit lines. It also provides mutual funds, insurance and stock brokerage, foreign exchange, leasing, factoring, financial consulting, investment management, foreign trade and mortgage financing, treasury, and transactional services, as well as specialized services to finance projects for the real estate industry. In addition, the company offers short-term financing and fund raising, and brokerage services, as well as derivatives, securitization, and other tailor-made products. It serves individuals, small to middle-sized entities, companies, and large corporations, as well as universities, government entities, and local and regional governments. As of December 31, 2020, the company operated 358 branches, which include 220 under the Santander brand name, 19 under the Select brand name, 32 specialized branches for the middle market, and 28 as auxiliary and payment centers, as well as 1,199 ATMs. Banco Santander-Chile was incorporated in 1977 and is headquartered in Santiago, Chile.
Earnings Per Share
As for profitability, Banco Santander has a trailing twelve months EPS of $1.27.
PE Ratio
Banco Santander has a trailing twelve months price to earnings ratio of 14.59. Meaning, the purchaser of the share is investing $14.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.86%.
2. Century Communities (CCS)
31.1% sales growth and 12.64% return on equity
Century Communities, Inc., together with its subsidiaries, engages in the design, development, construction, marketing, and sale of single-family attached and detached homes. It is also involved in the entitlement and development of the underlying land; and provision of mortgage, title, and insurance services to its home buyers. The company offers homes under the Century Communities and Century Complete brands. It sells homes through its sales representatives, as well as through independent real estate brokers in 17 states in the United States. Century Communities, Inc. was founded in 2002 and is headquartered in Greenwood Village, Colorado.
Earnings Per Share
As for profitability, Century Communities has a trailing twelve months EPS of $9.01.
PE Ratio
Century Communities has a trailing twelve months price to earnings ratio of 8.79. Meaning, the purchaser of the share is investing $8.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.64%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 53.7% and a drop 5.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26%, now sitting on 3.89B for the twelve trailing months.
Sales Growth
Century Communities’s sales growth is 22.3% for the ongoing quarter and 31.1% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 29, 2024, the estimated forward annual dividend rate is 1.04 and the estimated forward annual dividend yield is 1.31%.
3. Terreno Realty Corporation (TRNO)
12.2% sales growth and 5.43% return on equity
Terreno Realty Corporation (“Terreno”, and together with its subsidiaries, the “Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these notes to the consolidated financial statements are unaudited. As of December 31, 2023, the Company owned 259 buildings aggregating approximately 16.0 million square feet, 45 improved land parcels consisting of approximately 152.4 acres, seven properties under development or redevelopment and approximately 62.7 acres of land entitled for future development. The Company is an internally managed Maryland corporation and elected to be taxed as a real estate investment trust (“REIT”) under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with its taxable year ended December 31, 2010.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $1.92.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 31.59. Meaning, the purchaser of the share is investing $31.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.43%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 28, 2024, the estimated forward annual dividend rate is 1.8 and the estimated forward annual dividend yield is 2.97%.
Yearly Top and Bottom Value
Terreno Realty Corporation’s stock is valued at $60.65 at 11:22 EST, below its 52-week high of $66.63 and way higher than its 52-week low of $50.42.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 333.97M for the twelve trailing months.
4. CoreSite Realty Corporation (COR)
9.9% sales growth and 213.15% return on equity
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options — all of which leads to a best-in-class customer experience and lasting relationships.
Earnings Per Share
As for profitability, CoreSite Realty Corporation has a trailing twelve months EPS of $9.14.
PE Ratio
CoreSite Realty Corporation has a trailing twelve months price to earnings ratio of 24.19. Meaning, the purchaser of the share is investing $24.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 213.15%.
5. Kamada Ltd. (KMDA)
7.2% sales growth and 5.9% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.23.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 25.22. Meaning, the purchaser of the share is investing $25.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.9%, now sitting on 149.54M for the twelve trailing months.
Sales Growth
Kamada Ltd.’s sales growth is 6% for the present quarter and 7.2% for the next.
Yearly Top and Bottom Value
Kamada Ltd.’s stock is valued at $5.80 at 11:22 EST, way under its 52-week high of $6.53 and way higher than its 52-week low of $4.08.
